# A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

> **NCT02117622** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1056 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT02117622
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-24
- **Primary completion:** 2017-04-05
- **Final completion:** 2017-04-05
- **Target enrollment:** 1056 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117622, "A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02117622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*